Price movement over the last 24 hours
Adecoagro SA vs Heron Therapeutics Inc — how do they compare? Adecoagro SA trades at $10.17 (market cap $1.39B), while Heron Therapeutics Inc trades at $0.43 (market cap $80.58M). The key difference: Adecoagro SA is far larger — about 17.2× Heron Therapeutics Inc's market cap, and Adecoagro SA pays a 3.08% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AGRO | HRTX | |
|---|---|---|
Market Cap | $1.39B | $80.58M |
Sector | Technology | Health |
52-Week High | $15.25 | $2.23 |
52-Week Low | $7.13 | $0.39 |
Enterprise Value | $3.42B | $178.48M |
Dividend Yield | 3.08% | — |
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.
The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.
HRTX trades at $0.4339, down 1.03% today, with neutral technical signals and mixed earnings performance. The company reported a Q1 2026 loss of $0.04 per share, missing estimates, but maintains a strong gross margin of 71.12% and a low P/S ratio of 0.47. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite quarterly pressures.
Outlook remains speculative given persistent net losses and negative cash flow from operations, though analyst consensus is overwhelmingly bullish with 94.74% buy ratings. Key risks include execution challenges and competitive threats in the biotechnology sector, while potential upside hinges on achieving profitability and successful product commercialization.
Trailing returns across standard periods
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →